- Home
- TWST vs HCM Comparison
TWST vs HCM Comparison
Compare TWST & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWST
- HCM
- Stock Information
- Founded
- TWST 2013
- HCM 2000
- Country
- TWST United States
- HCM Hong Kong
- Employees
- TWST N/A
- HCM N/A
- Industry
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- TWST Health Care
- HCM Health Care
- Exchange
- TWST Nasdaq
- HCM Nasdaq
- Market Cap
- TWST 2.3B
- HCM 2.6B
- IPO Year
- TWST 2018
- HCM N/A
- Fundamental
- Price
- TWST $27.08
- HCM $17.44
- Analyst Decision
- TWST Buy
- HCM
- Analyst Count
- TWST 9
- HCM 0
- Target Price
- TWST $50.67
- HCM N/A
- AVG Volume (30 Days)
- TWST 1.4M
- HCM 57.4K
- Earning Date
- TWST 08-04-2025
- HCM 08-07-2025
- Dividend Yield
- TWST N/A
- HCM N/A
- EPS Growth
- TWST N/A
- HCM N/A
- EPS
- TWST N/A
- HCM 0.53
- Revenue
- TWST $362,273,000.00
- HCM $602,197,000.00
- Revenue This Year
- TWST $22.12
- HCM $2.73
- Revenue Next Year
- TWST $17.27
- HCM $17.33
- P/E Ratio
- TWST N/A
- HCM $6.26
- Revenue Growth
- TWST 22.72
- HCM N/A
- 52 Week Low
- TWST $24.07
- HCM $11.51
- 52 Week High
- TWST $55.33
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- TWST 49.12
- HCM 60.43
- Support Level
- TWST $24.07
- HCM $15.51
- Resistance Level
- TWST $25.96
- HCM $18.30
- Average True Range (ATR)
- TWST 1.30
- HCM 0.35
- MACD
- TWST 0.28
- HCM 0.29
- Stochastic Oscillator
- TWST 78.80
- HCM 76.18
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.